- Home
- PHUN vs APLT Comparison
PHUN vs APLT Comparison
Compare PHUN & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | APLT |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9M | 38.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PHUN | APLT |
|---|---|---|
| Price | $1.96 | $0.13 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $7.25 | $1.25 |
| AVG Volume (30 Days) | 149.2K | ★ 8.6M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,357,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | $73.07 | $66.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.77 | $0.10 |
| 52 Week High | $6.29 | $1.50 |
Technical Indicators
Market Signals| Indicator | PHUN | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 27.06 |
| Support Level | $1.77 | $0.10 |
| Resistance Level | $2.12 | $0.13 |
| Average True Range (ATR) | 0.11 | 0.02 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 45.24 | 17.28 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.